Renalytix Plc (AIM:RENX)
London · Delayed Price · Currency is GBP · Price in GBX 5.35
-0.10 (-1.76%)
Oct 16, 2026, 1:09 PM GMT
Renalytix Earnings Call Transcripts
Fiscal Year 2026
-
A national distribution deal with Quest Diagnostics will provide access to half of U.S. physicians and hospitals, enabling a major scale-up for KidneyIntelX, an FDA-approved prognostic test for chronic kidney disease. Financials are strengthened, costs are controlled, and the company targets 25,000 tests in 2027, with global expansion and pharma collaborations underway.
Fiscal Year 2025
-
Revenue is on track for $3.2M in FY2025 with 20% quarterly growth, driven by Medicare coverage and direct-to-doctor sales. Operational improvements have reduced costs and turnaround times, while strategic pharma collaborations and a strong US focus support future expansion.